
    <html>
    <head><title>CRDL.TO</title>
<style>
body {
  font-family: Arial, sans-serif;
  margin: 20px;
}
.container {
  display: grid;
  grid-template-columns: 50% 50%;
  grid-template-rows: auto auto;
  gap: 20px;
}
img {
  width: 100%;
  height: auto;
  max-height: 400px;
  border: 1px solid #ccc;
  object-fit: contain;
}

.cell {
  padding: 10px;
}
.table-scroll {
  max-height: 400px;
  overflow-y: auto;
  border: 1px solid #aaa;
}
table {
  width: 100%;
  border-collapse: collapse;
}
th, td {
  border: 1px solid #aaa;
  padding: 5px;
  text-align: left;
  font-size: 14px;
}
.negative {
  background: linear-gradient(to right, #ffdddd, white);
}
.positive {
  background: linear-gradient(to right, white, #ddffdd);
}
.pos-light  { background: #e6ffe6; }  
.pos-mid    { background: #99ff99; }  
.pos-strong { background: #33cc33; }   

.neg-light  { background: #ffe6e6; }   
.neg-mid    { background: #ff9999; }   
.neg-strong { background: #ff3333; }   

h2 { border-bottom: 2px solid #444; }
<script>
function toggleText(id) {
  const moreText = document.getElementById(id);
  const btn = document.getElementById(id + "_btn");

  if (moreText.style.display === "none") {
    moreText.style.display = "inline";
    btn.innerText = " Show less";
  } else {
    moreText.style.display = "none";
    btn.innerText = " Show more";
  }
}
</script>
</style>
</head>
    <body>
    <h2> CRDL.TO  
        <span style='font-weight:normal; font-size: 18px;'>(41d - clinical trial milestone)</span>
        <span style='color:darkred; font-weight:bold; font-size: 20px;'> 10D NEG</span>
        <a href='https://finance.yahoo.com/chart/CRDL.TO?interval=1mo' target='_blank'>Yahoo</a>
        <span style='font-weight:600;'>  —  — now: 1.38</span>
    </h2>

    <div class="container">
        <div class="cell"><p><i>No image</i></p></div>
        <div class="cell"><div style='display:flex; gap:10px; align-items:flex-start'>  <div style='flex:0 0 50%'><a href='https://vosorin.github.io/100__2025_06_public/RAPORT/B_ZOOM_CRDL.TO_ALL.jpg' target='_blank'>    <img src='B_ZOOM_CRDL.TO_ALL.jpg' alt='B_ZOOM_CRDL.TO_ALL.jpg'></a></div>  <div style='flex:0 0 50%'><a href='https://vosorin.github.io/100__2025_06_public/RAPORT/B_CRDL.TO_BAND.jpg' target='_blank'>    <img src='B_CRDL.TO_BAND.jpg' alt='B_CRDL.TO_BAND.jpg'></a></div></div></div>
        <div class="cell"><div style='display:flex;gap:10px;align-items:flex-start'><a href="https://vosorin.github.io/100__2025_06_public/RAPORT/A_CRDL.TO_10d_neg_ZOOM.png" target="_blank"><img src="A_CRDL.TO_10d_neg_ZOOM.png" alt="A_CRDL.TO_10d_neg_ZOOM.png"></a><a href="https://vosorin.github.io/100__2025_06_public/RAPORT/A_CRDL.TO_10d_neg.jpg" target="_blank"><img src="A_CRDL.TO_10d_neg.jpg" alt="A_CRDL.TO_10d_neg.jpg"></a></div></div>
        <div class="cell"><div class='table-scroll'><table><tr><th>Date</th><th>Score</th><th>AMR</th><th>Type</th><th>Summary</th><th>Links</th></tr><tr class='pos-light'><td>2025-11-19</td><td>0.35</td><td></td><td>analyst meetings</td><td>0.35 local feel              __   CRDL.TO __    -> i:0.35<-                      <br><br>FEELING: total score +0.35 Here's a breakdown of the scoring: Analyst Ratings: 3 analysts recommend BUY (+0.1). While the consensus is positive, the lack of a clear consensus across all analysts limits the score. Price Target: The average price target of $7.33 represents a substantial potential gain (355.49% growth). This is a significant positive signal, contributing +0.3. Backward-Looking Data: The news contains a lot of backward-looking data (past year trends, EPS history, YTD loss, etc.). This receives a very low score and is largely discounted. EPS Estimates: The news mentions next quarter EPS: -0.09, next year EPS estimate: -0.39. These are negative, but the focus is on potential, so the impact is minimal. Volume: Above-average trading volume (0.99M shares traded) suggests increased investor interest, contributing a slight +0.05. --- <br> - OmniAb (OABI) shows potential for significant upside with a strong buy rating consensus and a 12-month average price target of $7.33, representing a substantial potential gain. Monitor EPS growth and short interest trends. <br><br>*** REZUMAT *** - OABI stock poised to outperform peers. - Volume: 0.99M shares traded, above average (0.55M). - 52-week range: $1.22 - $4.21. - 1-year price target: $7.33. - Beta: 0.17. - 3-month performance: -12.02%. - 6-month performance: +4.55%. - 1-year loss: -54.52%. - YTD loss: -60.44%. - Trailing 12-month EPS: -0.59. - Next year EPS estimate: -0.39. - Next quarter EPS: -0.09. - Outstanding shares: 143.96M. - Float: 109.05M. - Short shares (2025-10-31): 5.76M. - Revenue (2025-09-30): $2.24M. - Operating income (2025-09-30): -$18.14M. - EBITDA (2025-09-30): -$13.49M. - Diluted EPS (2025-09-30): -$0.14. - 3 analysts recommend BUY, 0 recommend SELL. - Average target price: $7.33 (potential 355.49% growth). - High target price: $11.0 (potential 583.23% growth). - Low target price: $3.0 (potential 86.34% growth).   (gemma3:12b-it-q4_K_M on 2025-11-19 20:17:05)</td><td><a href='https://setenews.com/2025/11/19/stocks-of-omniab-inc-oabi-are-poised-to-climb-above-their-peers/' target='_blank'>Link</a></td></tr><tr class='pos-mid'><td>2025-11-17</td><td>0.40</td><td>1457</td><td>Credit facility update</td><td>0.4 local feel              __   CRDL.TO __    -> i:0.4<-                     **   ** 2029-11-17 **   <br><br>** 2029-11-17  Credit facility update ***<br>FEELING: total score 0.4 Breakdown: credit facilities (+0.2): Securing new credit facilities, especially with favorable terms (6.74% interest), indicates financial strength and access to capital. buyback programs (+0.1): The announcement of a normal course issuer bid (NCIB) for up to 10% of the public float is generally viewed positively, signaling management's confidence in the company's value. favorable resolution (+0.1): Repaying existing credit facilities maturing in March 2026 is a positive step, resolving a potential future obligation. forward-looking statements (-0.1): The disclaimer about risks inherent in forward-looking statements slightly reduces the overall positive sentiment. Note: The news focuses on financial actions and future plans, which are given higher weight. The therapeutic area focus is considered background information and receives a very low score. --- <br> - Medexus securing US$51 million in new credit facilities and planning a share buyback demonstrates financial strength and a proactive capital allocation strategy. Investors should view this as a positive sign, potentially indicating future growth and shareholder value creation, though risks remain inherent in forward-looking statements. <br><br>*** REZUMAT *** - Medexus secured US$51 million in new credit facilities from National Bank of Canada. - The facilities include a US$21 million term loan, US$5 million revolving loan, and US$25 million additional features. - Interest rate initially at 6.74%, favorable compared to previous facilities. - Proceeds used to repay existing credit facilities maturing in March 2026. - Medexus intends to commence a normal course issuer bid (NCIB) for up to 10% of its public float. - NCIB aims to potentially uphold a liquid and orderly market for common shares. - Company focuses on hematology/oncology and rheumatology/allergy therapeutic areas.   (gemma3:12b-it-q4_K_M on 2025-11-17 22:48:33)</td><td><a href='https://investingnews.com/medexus-announces-us-51-0-million-in-new-credit-facilities-and-intention-to-commence-normal-course-issuer-bid-or-ncib-for-its-common-shares/' target='_blank'>Link</a></td></tr><tr class='pos-mid'><td>2025-11-17</td><td>0.40</td><td></td><td>product launch</td><td>0.4 local feel              __   CRDL.TO __    -> i:0.4<-                      <br><br>FEELING: total score +0.4 Reasoning: The primary event here is the FDA or Canada Health decisions (approval granted: +0.4). The approval of a new 45mg LUPRON DEPOT strength for advanced prostate cancer is a positive development. It expands treatment options, potentially boosts AbbVie's market share, and reinforces its commitment to oncology. While the news mentions monitoring prescription uptake and the competitive landscape, the initial approval itself is a significant, forward-looking event. The long history of the drug (36 years) and past prevalence data are backward-looking and receive a very low score. The mention of AbbVie's commitment to patients is promotional language and receives a very low score. --- <br> - This Health Canada approval for a new 45mg LUPRON DEPOT strength expands treatment options for advanced prostate cancer, potentially boosting AbbVie's market share and reinforcing its commitment to oncology. Investors should monitor prescription uptake and competitive landscape. <br><br>*** REZUMAT *** - AbbVie's LUPRON DEPOT received Health Canada approval for a new 45mg strength. - New strength targets advanced prostate cancer, offering a 6-month dosing option. - LUPRON DEPOT now available in four dosing options (1, 3, 4, & 6 months). - Initial approval was in 1989; 36 years of clinical use in Canada. - Prostate cancer is prevalent; 1 in 8 Canadian men will develop it. - AbbVie aims to improve lives; long-term commitment to patients. - LUPRON DEPOT suppresses sex hormones (testosterone, estrogen).   (gemma3:12b-it-q4_K_M on 2025-11-17 22:49:36)</td><td><a href='https://investingnews.com/lupron-depot-r-new-strength-receives-health-canada-approval-for-the-treatment-of-advanced-prostate-cancer/' target='_blank'>Link</a></td></tr><tr class='pos-light'><td>2025-11-14</td><td>0.30</td><td>41</td><td>clinical trial milestone</td><td>0.3 local feel              __   CRDL.TO __    -> i:0.5<-                     **   ** 2026-01-01 **   <br><br>** 2026-01-01  clinical trial milestone ***<br>FEELING: total score 0.3 Here's a breakdown of the scoring: Analyst reiterates "Buy" rating, $9.00 price target: +0.1 (Analyst meetings - low score, but positive) Promising pipeline (CardiolRx, CRD-38): +0.1 (Product launches - potential, but not yet realized) Positive insider activity: +0.1 (Generally positive signal, but not a huge driver) Extended cash runway into Q3 2027: +0.1 (Financial stability - positive, but not transformative) MAVERIC trial is key to watch: 0 (Future event, potential impact, but not guaranteed) ARCHER data (myocarditis) viewed as promising: +0.05 (Positive data, but already known) The news is largely positive, focusing on future potential and current stability. However, it lacks any truly transformative elements. --- <br> - Analyst reiterates a "Buy" rating with a $9.00 price target, citing Cardiol Therapeutics' promising pipeline (CardiolRx, CRD-38), positive insider activity, and extended cash runway into Q3 2027. The MAVERIC trial is key to watch. <br><br>*** REZUMAT *** - Analyst Brandon Folkes maintains a "Buy" rating, target price $9.00. - CardiolRx targets cardiac inflammation; avoids THC-related concerns. - CRD-38 is a subcutaneous formulation targeting heart failure. - MAVERIC Phase III trial for pericarditis; data expected late 2026. - ARCHER data (myocarditis) viewed as promising despite initial reaction. - Cash runway extended to Q3 2027, ensuring financial stability. - Positive insider activity observed over the last quarter.   (gemma3:12b-it-q4_K_M on 2025-11-14 19:48:17)</td><td><a href='https://www.tipranks.com/news/ratings/cardiol-therapeutics-promising-pipeline-and-financial-stability-support-buy-rating-ratings' target='_blank'>Link</a></td></tr><tr class='pos-light'><td>2025-10-29</td><td>0.30</td><td></td><td>FDA or Canada Health decisions</td><td>0.3 local feel              __   CRDL.TO __    -> i:0.3<-                      <br><br>FEELING: total score +0.3 Reasoning: The news primarily revolves around the efficacy and potential label expansion of VYVGART, Argenx's key product. Here's a breakdown of the contributing factors: Product Launches/Clinical Trial Results: The data presented at AANEM/MGFA and the ADAPT SERON trial results demonstrating efficacy (MSE achievement, MG-ADL score improvement, steroid reduction) are positive developments. This contributes +0.2. FDA or Canada Health decisions: The mention of "FDA label expansion" signals a potential future approval, which is a significant positive catalyst. This adds +0.1. Long-term data: The long-term data regarding steroid reductions (average 50% decrease) is a positive indicator of sustained benefit and patient adherence, contributing +0.1. Adolescent population: Benefit shown in adolescent gMG patients is a positive sign for market expansion. This adds +0.05. The news lacks any negative elements like lawsuits, debt restructuring, or management changes. The focus is on positive clinical data and future potential. --- <br> - Argenx's data showcasing VYVGART's efficacy across various gMG subtypes, including seronegative patients, and its ability to reduce steroid use, are highly encouraging. Investors should monitor FDA label expansion and long-term safety data. <br><br>*** REZUMAT *** - Argenx presented data at AANEM/MGFA highlighting VYVGART's efficacy in generalized myasthenia gravis (gMG). - ~60% of VYVGART gMG patients achieved minimal symptom expression (MSE), sustained for at least 4 weeks. - >70% of patients meaningfully reduced glucocorticoid use while maintaining clinical benefit. - ADAPT SERON trial met endpoint, showing a 3.35 point improvement in MG-ADL score. - VYVGART showed benefit in adolescent gMG patients (ages 12-17). - Long-term VYVGART treatment associated with substantial steroid reductions (avg. 50% decrease). - VYVGART SC treatment demonstrated sustained MSE in AChR-Ab+ participants.   (gemma3:12b-it-q4_K_M on 2025-10-29 21:03:08)</td><td><a href='https://investingnews.com/argenx-presents-new-data-at-aanem-and-mgfa-highlighting-the-strength-and-broad-benefit-of-vyvgart-for-myasthenia-gravis-patients/' target='_blank'>Link</a></td></tr><tr class='pos-light'><td>2025-10-28</td><td>0.30</td><td></td><td>FDA or Canada Health decisions</td><td>0.3 local feel              __   CRDL.TO __    -> i:0.3<-                      <br><br>FEELING: total score 0.3 Reasoning: The news primarily focuses on potential future gains and FDA/Health decisions, which are significant drivers for biotech stocks. Specifically for CRDL.TO, the "ARCHER trial showed encouraging results potential 809% gain" triggers a positive score. This falls under the "FDA or Canada Health decisions" event, with a potential upside of 0.4. The high potential gain suggests a significant positive catalyst. The valuation mentioned is irrelevant to the score. The other companies mentioned are not relevant to the score. --- <br> - These five under-the-radar biotech stocks present high-risk, high-reward opportunities, particularly with potential upside exceeding 900% for some. Monitor developments, especially FDA decisions and clinical trial results, as these will significantly impact stock performance. <br><br>*** REZUMAT *** - INO: Valued at $123.8B, developing DNA-based medicines; BLA submission expected in 2H 2025, potential 425% gain. - TERN: Valued at $679.9B, focusing on oncology & obesity; discontinued TERN-601, TERN-701 showing promise; potential 257% gain. - CRDL: Valued at $145.02M, developing therapies for heart diseases; ARCHER trial showed encouraging results; potential 809% gain. - SLN: Valued at $344.8M, developing siRNA medicines; Phase 2 trial enrollment complete for divesiran; potential 943% gain. - ATRA: Valued at $196.7M, developing T-cell immunotherapies; FDA accepted BLA for tab-cel, decision expected Jan. 2026; potential 96% gain.   (gemma3:12b-it-q4_K_M on 2025-10-28 21:22:49)</td><td><a href='https://www.barchart.com/story/news/35724198/5-under-the-radar-biotech-stocks-that-could-soar-in-2026' target='_blank'>Link</a></td></tr><tr class='pos-light'><td>2025-10-27</td><td>0.30</td><td></td><td>FDA or Canada Health decisions</td><td>0.3 local feel              __   CRDL.TO __    -> i:0.3<-                      <br><br>FEELING: total score 0.3 Reasoning: The primary event here is the ongoing Phase 3 clinical trial (MAVERIC) for CardiolRx. While the news highlights "promise" and potential to "significantly boost the company's market position," it's crucial to acknowledge this is contingent on the trial's ultimate success. Here's the breakdown: FDA or Canada Health decisions: (0.4) - The news refers to a Phase 3 trial, which is a significant step towards potential regulatory approval. The "promise" suggests a favorable outcome is anticipated, but it's not a guaranteed approval yet. product launches: (0.2) - The successful outcome of the trial would effectively be a product launch, so a small positive score is warranted. analyst meetings: (0.0) - No analyst meetings are mentioned. Other factors: The news mentions monitoring trial progress and the competitive landscape, indicating uncertainty. This tempers the positive sentiment. The overall score reflects the potential upside but acknowledges the inherent risk associated with clinical trials. --- <br> - Cardiol Therapeutics' Phase 3 trial (MAVERIC) evaluating CardiolRx for recurrent pericarditis shows promise. Positive results could significantly boost the company's market position, but investors should monitor trial progress and competitive landscape. <br><br>*** REZUMAT *** - Cardiol Therapeutics (CRDL) conducting Phase 3 MAVERIC trial. - Trial assesses CardiolRx effectiveness in preventing pericarditis recurrence. - Study began November 25, 2024, latest update October 1, 2025. - CardiolRx is an oral drug, administered twice daily. - Randomized, double-blind, placebo-controlled design. - Focuses on preventing recurrence after IL-1 blocker cessation. - Trial currently recruiting, details on ClinicalTrials portal.   (gemma3:12b-it-q4_K_M on 2025-10-27 20:28:37)</td><td><a href='https://www.tipranks.com/news/company-announcements/cardiol-therapeutics-phase-3-trial-a-potential-game-changer-in-recurrent-pericarditis-treatment' target='_blank'>Link</a></td></tr></table></div></div>
    </div>
    </body>
    </html>
    